期刊
FRONTIERS IN IMMUNOLOGY
卷 10, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2019.00309
关键词
graft-vs.-host disease; immune tolerance; alpha-1 antitrypsin; allogeneic hematopoietic stem cell transplantation; T regulatory cells
类别
资金
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- National Heart, Lung, and Blood Institute
- National Cancer Institute [R01 HL56067, HL1181879, AI34495]
- Canadian Institutes of Health Research (CIHR) fellowship
Acute graft-vs.-host disease (GVHD) limits the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), a main therapy to treat various hematological disorders. Despite rapid progress in understanding GVHD pathogenesis, broad immunosuppressive agents are most often used to prevent and remain the first line of therapy to treat GVHD. Strategies enhancing immune tolerance in allo-HSCT would permit reductions in immunosuppressant use and their associated undesirable side effects. In this review, we discuss the mechanisms responsible for GVHD and advancement in strategies to achieve immune balance and tolerance thereby avoiding GVHD and its complications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据